Mallinckrodt, Inc.

Washington University

Mallinkrodt Inc.

Mallinkcrodt, Inc.

Samuel I Achilefu

Raghavan Rajagopalan

Richard Bradley Dorshow

Joseph E Bugaj

Muthunadar P Periasamy

Gary Lee Cantrell

Yang Liu

Joseph P Culver

Viktor Gruev

Walter Akers

Rui Tang

Adam Bauer

Hermo N Jimenez

Kexian Liang

Kvar Black

Gregory M Lanza

Partha Karmakar

Gail Sudlow

Duanwen Shen

Grace Hufang Cui

Christopher Egbulefu

Avik Som

Nalinikanth Kotagiri

Baogang Xu

Yunpeng Ye

Pratim Biswas

Mikhail Y Berezin

Arthur H Combs

Ramesh Raliya

Zongren Zhang

Hyeran Lee

John Christian Mason

Hyeran Lee, Legal Representative

Joseph E Bugai

Richard D Dorshow

Joseph B Bugaj

The present invention encompasses compositions comprising two spectrally distinct radionuclides separated by a site susceptible to cleavage. Compositions of the invention may be used to detect enzyme activity and/or image diseases associated with said enzyme activity.

Compositions and methods for treatment and imaging using nanoparticles

A goggle system is provided. The goggle system includes a computing device, a goggle device configured to be worn by a user and including a detector configured to simultaneously acquire image data of a subject in a first image mode and a second image mode, at least one eye assembly configured to display at least one of an image in the first image mode, an image in the second image mode, and a hybrid image including pixels of image data from the first image mode and pixels of image data from the second image mode, and a communications module configured to transmit acquired image data from the goggle device to the computing device.

Imaging systems and methods

The present disclosure discloses methods and compositions for administering Cerenkov radiation-induced therapy (CRIT).

Imaging and treatment of pathophysiologic conditions by Cerenkov radiation

Provided herein is a pharmaceutical composition comprising an effective amount of cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301), cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Tyr-OH (LS838) or pharmaceutically acceptable salts thereof, wherein each amino acid residue is independently in a D or L configuration; a divalent metal ion; and a pharmaceutically acceptable carrier. Further provided are lyophilized products comprising a dye-conjugate and m methods for identifying compromised and for binding phosphorylated annexin A2 (pANXA2) protein in a biological sample using a composition described herein.

Near infrared fluorescent dyes, formulations and related methods

Goggle imaging systems and methods

The present invention provides compounds that have motifs that target the compounds to cells that express integrins. In particular, the compounds have peptides with one or more RD motifs conjugated to an agent selected from an imaging agent and a targeting agent. The compounds may be used to detect, monitor and treat a variety of disorders mediated by integrins.

Compounds having RD targeting motifs and methods of use thereof

The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds.

Dichromic fluorescent compounds

The present disclosure discloses methods and compositions for administering Cerenkov radiation-induced therapy (CRIT). In an aspect, the invention encompasses a composition comprising at least two radiation-sensitive molecules. In another aspect, the invention encompasses a composition comprising a radiation-sensitive molecule and a targeting agent. In still another aspect, the invention encompasses a method for administering Cerenkov radiation-induced therapy (CRIT) to a target tissue in a subject. The method comprises administering to the subject an effective amount of a composition B comprising at least one radiation-sensitive molecule and administering to the subject an amount of a Cerenkov radiation (CR)-emitting radionuclide effective to activate the radiation-sensitive molecule, thereby administering CRIT to the target tissue in the subject.

The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.

Homing agents

A compound of formula (I) is provided having the structure: cypate-cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH, and each amino acid is independently in a D or L configuration. Also provided are pharmaceutical compositions that include the compound of formula (I) and its use in treating cancer by administering it to a patient in need thereof.

Growing community of inventors

Dallas, TX, United States of America

Samuel I Achilefu